✦ LIBER ✦

EORTC-IDBBC (Investigational Drug Branch For Breast Cancer): 5 Years of European collaboration in new drug development for breast cancer

✍ Scribed by A Awada; A Van Vreckem; R Paridaens; P.F Bruning; J Klijn; E Tomiak; J Vinholes; J.A Roy; Z Kusenda; G Hoctin Boes; M Van Glabbeke; M.J Piccart

Book ID: 117663833
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 374 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)00085-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

EORTC-IDBBC (Investigational Drug Branch

EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): Seven years of active European collaboration

✍ A. Awada; T. Cufer; L. Beex; R. Coleman; R. Paridaens; P. Bruning; J. Klijn; M. 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 147 KB

710 - Docetaxel (D) in combination with

710 - Docetaxel (D) in combination with amifostine (A) in metastatic breast cancer (MBC): A feasibility and pharmacoklnetlc study of the EORTC-investigational drug branch for breast cancer (IDBBC)

✍ A. Awada; D. de Valériola; N. Cornez; J. Kerger; A. Van Vreckem; S. Bartholomeus 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 216 KB

347 Steroids do reduce the severity and

347 Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: Final results of a randomized trial of the EORTC investigational drug branch for breast cancer (IDBBC)

✍ M.J. Piccart; J. Klijn; R. Paridaens; M. Nooij; L. Mauriac; R. Coleman; A. Awada 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 126 KB

Entry and evaluation of elderly patients

Entry and evaluation of elderly patients in european organization for research and treatment of cancer (EORTC) new-drug–development studies

✍ Silvio Monfardini; Roberto Sorio; Guido Hoctin Boes; Stan Kaye; Diego Serraino 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 495 KB 👁 3 views

5BA Clinical validation of in vitro drug

5BA Clinical validation of in vitro drug sensitivity microarray data: regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00-01)

✍ H. Bonnefoi; A. Potti; L. Mauriac; M. Tubiana-Hulin; M. Campone; D. Cameron; J. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 40 KB